Sun Pharmaceutical Industries and Concert Pharmaceuticals, Inc. entered a definitive agreement under which Sun Pharma will acquire Concert through an upfront payment of $576 million. Concert stockholders will also receive up to an additional $3.50 per share of common stock in cash, payable upon deuruxolitinib achieving certain sales milestones.   Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, incl...